Compare NVRI & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVRI | HQL |
|---|---|---|
| Founded | 1853 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Investment Managers |
| Sector | Miscellaneous | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.1M | 689.4M |
| IPO Year | 2026 | N/A |
| Metric | NVRI | HQL |
|---|---|---|
| Price | $20.65 | $19.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 255.4K | 133.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | ★ N/A | $24.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.15 | $14.06 |
| 52 Week High | $24.20 | $22.67 |
| Indicator | NVRI | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 35.27 |
| Support Level | $20.27 | $18.76 |
| Resistance Level | $23.68 | $21.32 |
| Average True Range (ATR) | 0.77 | 0.46 |
| MACD | -0.24 | -0.20 |
| Stochastic Oscillator | 6.11 | 7.05 |
Enviri Corp provides environmental and operational solutions to the metal and rail industries. It is based in Philadelphia, Pennsylvania, and operates in more than 30 countries. The company leverages industrial expertise to help customers improve operational performance, recover value from byproducts, enhance sustainability, and maintain critical infrastructure. Its divisions are Harsco Environmental and Harsco Rail, which combine deep operational capabilities with technologies and world-wide scale to deliver long-term value for customers, communities, and shareholders.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.